Oxalate | Jotup

Arbor Biotechnologies Announces Presentations at the 2023 Annual Meeting of the American Society of Gene & Cell Therapy

Retrieved on:

Tuesday, May 2, 2023

Kidney disease, Abstract, HAO1, Gene, Waste, Significant figures, American Society of Gene and Cell Therapy, Model, PH, Primary hyperoxaluria, Engineering, Annual general meeting, Cell, Oxalate, Society, Vaccine

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that three abstracts were selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held from May 16-20, 2023, in Los Angeles, CA.

Key Points:

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Arbor Biotechnologies®, a biotechnology company discovering and developing the next generation of genetic medicines, today announced that three abstracts were selected for poster presentation at the upcoming American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting being held from May 16-20, 2023, in Los Angeles, CA.
“Among our poster presentations, we will be providing early results with our lead product candidate, ABR-001—a novel type V CRISPR Cas, which we are developing for the treatment of primary hyperoxaluria, or PH.
PH is a rare, life-threatening condition that prevents the kidneys from filtering fluids and waste products from the body effectively, often resulting in end-stage renal disease.
We are highly encouraged by these preclinical results, which demonstrate that in vivo editing of the HAO1 gene with ABR-001 significantly reduced toxic oxalates in a mouse model of PH Type 1.

Energy Fuels Executes Definitive Agreement to Sell Alta Mesa ISR Project to enCore Energy for $120 Million, Facilitating the Company's Plans to Accelerate Both Uranium and Rare Earth Production

Retrieved on:

Monday, November 14, 2022

Once the reclamation liabilities are transferred to enCore, Energy Fuels will be nearly 60% collateralized on its remaining reclamation obligations.

Key Points:

Once the reclamation liabilities are transferred to enCore, Energy Fuels will be nearly 60% collateralized on its remaining reclamation obligations.
The Company also estimates that the sale of Alta Mesa will reduce Energy Fuels' cash burn by approximately $2 million per year.
Mark S. Chalmers, President and CEO of Energy Fuels stated: "This is a unique transaction for Energy Fuels.
Energy Fuels holds three of America's key uranium production centers: the White Mesa Mill in Utah, the Nichols Ranch ISR Project in Wyoming, and the Alta Mesa ISR Project in Texas.

Allena Pharmaceuticals to Participate in the 12th Annual Wedbush PacGrow Healthcare Conference

Retrieved on:

Tuesday, August 3, 2021

Medical specialties, Kidney diseases, Organs anatomy), Clinical medicine, Hyperoxaluria, Hyperuricemia, Kidney stone disease, Oxalate, Kidney, Uric acid, Chronic kidney disease

Management will also be available for 1x1 meetings onTuesday, August 10th Wednesday, August 11th, 2021.

Key Points:

Management will also be available for 1x1 meetings onTuesday, August 10th Wednesday, August 11th, 2021.
Allena Pharmaceuticals, Inc.is a biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.
Allenas lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study recently completed and a Phase 2a program planned for the second half of 2021.

Alnylam Reports Positive Topline Results from ILLUMINATE-C Phase 3 Study of Lumasiran in Patients with Advanced Primary Hyperoxaluria Type 1

Retrieved on:

Thursday, July 29, 2021

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.

Key Points:

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today positive topline results from the ILLUMINATE-C Phase 3 open-label study of lumasiran in patients of all ages with advanced primary hyperoxaluria type 1 (PH1) associated with progressive decline in renal function.
Results of the primary analysis at six months demonstrated substantial reduction in plasma oxalate from baseline in patients (N=21) with advanced disease, including those on hemodialysis.
Cohort A enrolled six patients with advanced PH1 who do not yet require dialysis, and Cohort B enrolled 15 patients who are hemodialysis-dependent.
Lumasiran also demonstrated positive results across key secondary endpoints, including measures of urinary oxalate (for patients in Cohort A) and additional measures of plasma oxalate.

Allena Pharmaceuticals, Inc. to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference

Retrieved on:

Thursday, July 8, 2021

Kidney diseases, Medical specialties, Organs anatomy), Clinical medicine, Hyperoxaluria, Hyperuricemia, Kidney stone disease, Oxalate, Chronic kidney disease, Kidney disease, Kidney, Uric acid

Allena Pharmaceuticals, Inc.is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.

Key Points:

Allena Pharmaceuticals, Inc.is a late-stage biopharmaceutical company dedicated to discovering, developing and commercializing first-in-class, oral biologic therapeutics to treat patients with rare and severe metabolic and kidney disorders.
Allenas lead product candidate, reloxaliase, is currently being evaluated in a pivotal Phase 3 clinical program for the treatment of enteric hyperoxaluria, a metabolic disorder characterized by markedly elevated urinary oxalate levels and commonly associated with kidney stones, chronic kidney disease and other serious kidney disorders.
Allena is also developing ALLN-346 for the treatment of hyperuricemia in the setting of gout and advanced chronic kidney disease, with a Phase 1 multiple-ascending dose study currently in progress and a Phase 2a program planned for the second half of 2021.

Synlogic Presents Additional Preclinical Data on Therapeutic Candidates SYNB1934 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria at Synthetic Biology: Engineering, Evolution & Design (SEED) Conference

Retrieved on:

Tuesday, June 15, 2021

Clinical medicine, Medical specialties, Medicine, Kidney diseases, Hyperoxaluria, Phenylketonuria, Nephrocalcinosis, Oxalate, Kidney stone disease, Synthetic biology

Data from preclinical in vivoand in vitrostudies demonstrated a greater than 2-fold improvement in the ability of SYNB1934 to metabolize Phe compared to SYNB1618.

Key Points:

Data from preclinical in vivoand in vitrostudies demonstrated a greater than 2-fold improvement in the ability of SYNB1934 to metabolize Phe compared to SYNB1618.
"The progression of SYNB1934 highlights Synlogic's ability to use synthetic biology to rapidly design and optimize Synthetic Biotic medicines with the potential for greater patient benefit.
Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis.
Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria.

Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Compositions and Uses of Tianeptine Oxalate Salt, the Active Ingredient of TNX-601 CR

Retrieved on:

Friday, March 19, 2021

Tonix Pharmaceuticals, Chemical compounds, Psychoactive drugs, Seth Lederman, Oxalate, Organic compounds, Tianeptine

Tianeptine oxalate is the active pharmaceutical ingredient of Tonixs development candidate, TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablet).

Key Points:

Tianeptine oxalate is the active pharmaceutical ingredient of Tonixs development candidate, TNX-601 CR (tianeptine oxalate and naloxone controlled-release tablet).
The new patent, Tianeptine Oxalate Salts and Polymorphs, includes claims directed to pharmaceutical compositions comprising crystalline tianeptine oxalate salts, to methods of using those compositions to treat various disorders, and to methods of producing the oxalate salts.
This patent is expected to provide Tonix with U.S. market exclusivity until December 28, 2037, excluding any patent term extensions.
We are pleased with the issuance of the new patent that protects pharmaceutical compositions and uses of salts of tianeptine oxalate, said Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals.

Dicerna Announces Enrollment Completion of PHYOX™2 Pivotal Trial of Nedosiran for Treatment of Primary Hyperoxaluria

Retrieved on:

Monday, January 4, 2021

The PHYOX2 multicenter pivotal trial (NCT03847909) is designed to evaluate the efficacy and safety of nedosiran delivered as a once-monthly subcutaneous injection in participants aged six years and older who have PH1 or PH2.

Key Points:

The PHYOX2 multicenter pivotal trial (NCT03847909) is designed to evaluate the efficacy and safety of nedosiran delivered as a once-monthly subcutaneous injection in participants aged six years and older who have PH1 or PH2.
The primary endpoint of the study is the percent change from baseline in 24-hour urinary oxalate excretion between Days 90 and 180.
Enrollment of 35 participants was completed in December 2020 and included participants across 11 countries, including the U.S., Japan and Europe.
Primary hyperoxaluria (PH) is a family of ultra-rare, life-threatening genetic disorders that initially manifest with complications in the kidneys.

Synlogic Presents SYNB8802 for Enteric Hyperoxaluria at the American Institute of Chemical Engineers Conference on Microbiome Engineering

Retrieved on:

Monday, December 7, 2020

Medical specialties, Clinical medicine, Kidney diseases, Medicine, Hyperoxaluria, Nephrocalcinosis, Kidney stone disease, Phenylketonuria, Oxalate, Primary hyperoxaluria

SYNB8802 will be assessed for safety and tolerability, and the potential to reduce urinary oxalate.

Key Points:

SYNB8802 will be assessed for safety and tolerability, and the potential to reduce urinary oxalate.
Enteric Hyperoxaluria results in dangerously high levels of urinary oxalate, which causes progressive kidney damage, kidney stone formation, and nephrocalcinosis.
Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX).
These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.

PANTHERx Rare® Pharmacy Chosen as Partner by Alnylam Pharmaceuticals for OXLUMO™ (lumasiran) for the Treatment of Primary Hyperoxaluria Type 1 (PH1) to Lower Urinary Oxalate Levels

Retrieved on:

Thursday, December 3, 2020

Kidney diseases, Hyperoxaluria, Primary hyperoxaluria, Medical specialties, Clinical medicine, Lumasiran, Medicine, Hydroxyacid oxidase (glycolate oxidase) 1, Oxalate, Urinary system

The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.

Key Points:

The drug has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.
OXLUMO met the primary efficacy endpoint of percent reduction from baseline in 24-hour urinary oxalate excretion corrected for BSA, averaged over Months 3 through 6.
"We are honored to partner with Alnylam and provide PANTHERx's award-winning RxARECARE services to people living with primary hyperoxaluria type 1," said Dr. Gordon Vanscoy, Chairman & CEO of PANTHERx Rare.
OXLUMO is an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) for the treatment of primary hyperoxaluria type 1 (PH1) to lower urinary oxalate levels in pediatric and adult patients.